SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

 - Total proceeds expected to be approximately $230 million, combining funds held in Helix Acquisition Corp's trust account and a private investment in public entity (PIPE) financing - Leading institutional investors commit $115 million through a PIPE led by Cormorant Asset Management - Business combination is expected to be completed late in the fourth quarter of 2021 or early in the first quarter of 2022 - The combined company plans to advance clinical development of the tri-specific Nanobody® sonelokimab for the treatment of skin and joint diseases driven by IL-17A and IL-17F MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapi

SC 13D - MoonLake Immunotherapeutics (0001821586) (Subject)

SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)

SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)

SC 13G - Helix Acquisition Corp (0001821586) (Subject)

SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)

SC 13G - Helix Acquisition Corp (0001821586) (Subject)

SC 13G - Helix Acquisition Corp (0001821586) (Subject)

SC 13G - Helix Acquisition Corp (0001821586) (Subject)

SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)

S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)

S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)

8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

8-K/A - MoonLake Immunotherapeutics (0001821586) (Filer)

10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)

S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)

8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

8-K - Helix Acquisition Corp (0001821586) (Filer)

DEFA14A - Helix Acquisition Corp (0001821586) (Filer)